Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTx424
- Development stage
- Unknown
- Lead developer
- Primal Therapies
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
**PTx424** is a Primal Therapies pipeline asset described as a proprietary small-molecule combination within the company's SMMRT microbial-metabolism technology platform. Primal Therapies states that its platform uses small molecules, including prebiotics, postbiotics, and antimicrobials, to modulate biofilms and microbiomes by selectively suppressing unwanted microbes and favoring beneficial microbial activity; however, the specific constituents, molecular targets, indication, route, dosage form, and development stage of PTx424 have not been publicly disclosed. ([primaltherapies.com](https://primaltherapies.com/our-pipeline/))
Beyond the preview
Go deeper on PTx424.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTx424.